516
Views
35
CrossRef citations to date
0
Altmetric
Perspective

Advances in paediatric pharmacokinetics

, PharmD PhD (Professor of Individualized Drug Treatment) , , MSc (PhD candidate) & , PharmD PhD (Professor of Pharmacology)
Pages 1-8 | Published online: 30 Nov 2010

Bibliography

  • Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr 2005;164(9):552-8
  • Website of the Open TCI Iniatitive by the World Society of Intravenous Anaesthesia. Available from: www.opentci.org [Last accessed 1 September 2010]
  • Ince I, de Wildt SN, Tibboel D, Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. Drug Discov Today 2009;14(5-6):316-20
  • Website of the Dutch Top Institute Pharma. Available from: www.tipharma.com [Last accessed 1 September 2010]
  • De Cock RF, Piana C, Krekels EH, The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 2010: published online 26 March 2010, doi:10.1007/s00228-009-0782-9
  • Meibohm B, Laer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 2005;7(2):E475-87
  • Bazzoli C, Retout S, Mentre F. Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0. Comput Methods Programs Biomed 2010;98(1):55-65
  • Website for the winPOPT and POPT sofrware. Available from: www.winpopt.com [Last accessed 1 September 2010]
  • Website for the PopED software. Available from: poped.sourceforge.net [Last accessed 1 September 2010]
  • Website for the PopDes software from the University of Manchester. Available from: www.pharmacy.manchester.ac.uk/capkr/popdes [Last accessed 1 September 2010]
  • McDade EJ, Wagner JL, Moffett BS, Palazzi DL. Once-daily gentamicin dosing in pediatric patients without cystic fibrosis. Pharmacotherapy 2010;30(3):248-53
  • Inparajah M, Wong C, Sibbald C, Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy. Pharmacotherapy 2010;30(1):43-51
  • Lopez SA, Mulla H, Durward A, Tibby SM. Extended-interval gentamicin: population pharmacokinetics in pediatric critical illness. Pediatr Crit Care Med 2010;11(2):267-74
  • Sherwin CM, Svahn S, Van der LA, Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol 2009;65(7):705-13
  • Knibbe CA, Krekels EH, van den Anker JN, Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 2009;48(6):371-85
  • Anand KJ, Anderson BJ, Holford NH, Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth 2008;101(5):680-9
  • Allegaert K, de Hoon J, Verbesselt R, Maturational pharmacokinetics of single intravenous bolus of propofol. Paediatr Anaesth 2007;17(11):1028-34
  • De Wildt SN, Kearns GL, Murry DJ, Ontogeny of midazolam glucuronidation in preterm infants. Eur J Clin Pharmacol 2010;66(2):165-70
  • Muchohi SN, Kokwaro GO, Ogutu BR, Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. Br J Clin Pharmacol 2008;66(4):529-38
  • Prins SA, van Dijk M, Van Leeuwen P, Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. Paediatr Anaesth 2008;18(7):582-92
  • Palmer GM, Atkins M, Anderson BJ, I.V. acetaminophen pharmacokinetics in neonates after multiple doses. Br J Anaesth 2008;101(4):523-30
  • Bressolle F, Rochette A, Khier S, Population pharmacokinetics of the two enantiomers of tramadol and O-demethyl tramadol after surgery in children. Br J Anaesth 2009;102(3):390-9
  • Allegaert K, van Schaik RH, Vermeersch S, Postmenstrual age and CYP2D6 polymorphisms determine tramadol o-demethylation in critically ill neonates and infants. Pediatr Res 2008;63(6):674-9
  • Website for the Simcyp software. Available from: www.simcyp.com [Last accessed 4 November 2010]
  • Website for the PK-Sim software. Available from: www.systems-biology.com/products/pk-sim.html [Last accessed 4 November 2010]
  • Johnson TN, Rostami-Hodjegan A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr anaesth 2010: published online 18 May 2010 DOI: 10.1111/j.1460-9592.2010.03323.x
  • Johnson TN, Rostami-Hodjegan A, Tucker GT. Clin Pharmacokinet 2006;45(9):931-56
  • Peeters MY, Prins SA, Knibbe CA, Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology 2006;104(3):466-74
  • Nedelman JR. On some “disadvantages” of the population approach. AAPS J 2005;7(2):E374-82
  • Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009;24(1):25-36
  • Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008;47(4):231-43
  • Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther 2007;82(1):17-20
  • Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 2009;11(3):558-69
  • Holford N. The visual predictive check – superiority to standard diagnostic (Rorschach) plots. PAGE 14 Abstract 738. 2005, Available from: www.page-meeting.org/default.asp?abstract=738 [Last accessed 1 September 2010]
  • Brendel K, Comets E, Laffont C, Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 2006;23(9):2036-49
  • Khachman D, Laffont CM, Concordet D. You have problems to interpret VPC? Try VIPER. PAGE 19 Abstract 1892. 2010, Available from: http://www.page-meeting.org/default.asp?abstract=1892 [Last accessed 4 November 2010]
  • Dodds PS, Rothman DH, Weitz JS. Re-examination of the “3/4-law” of metabolism. J Theor Biol 2001;209(1):9-27
  • Agutter PS, Wheatley DN. Metabolic scaling: consensus or controversy? Theor Biol Med Model 2004;16:1-13
  • Bokma F. Evidence against universal metabolic allometry. Funct Ecol 2004;18:184-7
  • Glazier DS. Beyond the ‘3/4-power law’: variation in the intra- and interspecific scaling of metabolic rate in animals. Biol Rev 2005;80(4):611-62
  • White CR, Cassey P, Blackburn TM. Allometric exponents do not support a universal metabolic allometry. Ecology 2007;88(2):315-23
  • Mahmood I. Theoretical versus empirical allometry: facts behind theories and application to pharmacokinetics. J Pharm Sci 2010;99(7):2927-33
  • Kolokotrones T, Van S, Deeds EJ, Fontana W. Curvature in metabolic scaling. Nature 2010;464(7289):753-6
  • Mahmood I. Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept. Drug Metabol Drug Interact 2009;24(1):57-81
  • Mahmood I. Prediction of drug clearance in children: impact of allometric exponents, body weight, and age. Ther Drug Monit 2007;29(3):271-8
  • Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol 2006;61(5):545-57
  • Johnson TN. The problem in scaling adult drug doses to children. Arch Dis Child 2008;93(3):190-1
  • Mahmood I. Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model? Br J Clin Pharmacol. Accepted 2010 DOI: 10.1111/j.1365-2125.2010.03802.x
  • Peeters MY, Allegaert K, Blusse van Oud-Alblas HJ, Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet 2010;49(4):269-75
  • Wang C, Peeters MYM, Allegaert K, Scaling clearance of propofol from preterm neonates to adults using an allometric model with a bodyweight-dependent maturational exponent. PAGE 19 Abstract 1818 2010, Available from: www.page-meeting.org/default.asp?abstract=1818 [Last accessed 1 September 2010]
  • Ince I, De Wildt SN, Peeters MYM, Critical illness is a major determinant for midazolam and metabolite clearance in children. PAGE 19 Abstract 1819, Available from: www.page-meeting.org/default.asp?abstract=1819 [Last accessed 1 September 2010]
  • Anderson BJ, Larsson P. A maturation model for midazolam clearance. Paediatr Anaesth 2010: published online 23 July 2010, doi: 10.1111/j.1460-9592.2010.03364.x
  • Danhof M, de Jongh J, de Lange EC, Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 2007;47:357-400
  • Sharfstein JM, North M, Serwint JR. Over the counter but no longer under the radar – pediatric cough and cold medications. N Engl J Med 2007;357(23):2321-4

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.